RBC Capital Markets acted as Sole Placement Agent in a $30 million Series C financing for Mauna Kea Technologies

Transaction Information On January 23, 2008, Mauna Kea Technologies, a Paris-based medical technology company, closed a $30 million raise in a Series C financing. U.S.-based Psilos Group led the transaction with France-based Seventure and existing investor Creadev also participating. The net proceeds will be used for the commercialization of its proprietary Cellvizio imaging technology in the U.S. and Europe and to advance additional clinical applications of the platform. RBC Capital Markets acted as the Sole Placement Agent in this transaction. About Mauna Kea Technologies Mauna Kea Technologies leads the growing in vivo cellular imaging market enabling physicians to visualize, diagnose and treat pathologies that can not be seen using other imaging techniques. Mauna Kea Technologies' flagship Cellvizio system provides microscopic visualization of

mucosal tissue and promises to improve clinical outcomes by increasing the diagnostic yield of existing endoscopic procedures. With over 1,000 Cellvizio procedures completed to date, Mauna Kea Technologies is currently focused on the gastroenterology and pulmonology markets. The Company also has a distribution agreement with Leica Microsystems to sell products for the Small Animal Imaging market in Europe, the U.S. and Japan.

Summary Terms

Private Placement Offering Size: $30 million

Investment Banking Contact

Kevin Davies

Managing Director

Co-Head, U.S. Healthcare
212-428-6617
kevin.davies@rbccm.com